Follow-up: Webinar on drug repurposing for cancer in the COVID-19 era

The Anticancer Fund is one of the first philanthropic organisations to join the European Cancer Community 365

Webinar on drug repurposing for cancer in the COVID-19 area

Discover our strategic goals for 2020-2025

test

The Anticancer Fund supports EORTC trial in retroperitoneal sarcoma, a rare and aggressive cancer

The Anticancer Fund welcomes new members in the Advisory Board

A publication by scientists of the Anticancer Fund

Adoptive T cell therapy beneficial for metastatic melanoma patients that did not respond to standard of care immune therapy.

Els Verdegaal, Monique K van der Kooij, Marten Visser, Caroline van der Minne, Linda de Bruin, Pauline Meij, Anton Terwisscha van Scheltinga, Marij J Welters, Saskia Santegoets, Noel de Miranda, Inge Roozen, Gerrit Jan Liefers, Ellen Kapiteijn and Sjoerd H van der Burg (2020). Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study. Journal for ImmunoTherapy of Cancer., Vol. 8, Issue 1. doi.org/10.1136/jitc-2019-000166

More than 200 trials to fight COVID-19 worldwide